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TDP-43 is a primarily nuclear RNA-binding protein, whose abnormal phosphorylation and
cytoplasmic aggregation characterizes affected neurons in patients with amyotrophic lateral
sclerosis and frontotemporal dementia. Here, we report that physiological nuclear TDP-43 in
mouse and human brain forms homo-oligomers that are resistant to cellular stress.
Physiological TDP-43 oligomerization is mediated by its N-terminal domain, which can adopt
dynamic, solenoid-like structures, as revealed by a 2.1 Å crystal structure in combination with
nuclear magnetic resonance spectroscopy and electron microscopy. These head-to-tail
TDP-43 oligomers are unique among known RNA-binding proteins and represent the
functional form of the protein in vivo, since their destabilization results in loss of alternative
splicing regulation of known neuronal RNA targets. Our ﬁndings indicate that N-terminal
domain-driven oligomerization spatially separates the adjoining highly aggregation-prone,
C-terminal low-complexity domains of consecutive TDP-43 monomers, thereby preventing
low-complexity domain inter-molecular interactions and antagonizing the formation of
pathologic aggregates.
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Amyotrophic lateral sclerosis (ALS) and frontotemporaldementia (FTD) are two intimately related adult-onsetneurodegenerative disorders1. In ALS the loss of motor
neurons leads to fatal paralysis typically within 1–5 years of onset,
whereas FTD causes severe atrophy of the frontal and temporal
lobes leading to behavioral and language dysfunction2–5. The
RNA-binding protein (RBP) TDP-43 (Trans-activation response
element (TAR) DNA-binding protein 43) is mislocalized and
aggregated into neuronal cytoplasmic ubiquitinated inclusions in
the vast majority of ALS, as well as approximately half of FTD
cases2. Even though the loss of normal nuclear localization and
cytoplasmic TDP-43 aggregation correlates with neurodegenera-
tion, the exact mechanisms of neurotoxicity remain elusive.
Moreover, the molecular mechanisms triggering TDP-43
pathology in ALS and FTD remain poorly understood, in part
due to lack of high-resolution structural information of TDP-43
in the physiological and pathological state.
TDP-43 is a nucleo-cytoplasmic shuttling protein comprised of
two RNA recognition motifs (RRMs) that bind TG-/UG-repeat
nucleic acids in a sequence-speciﬁc fashion and are indispensable
for its roles in RNA metabolism3, 6–8. TDP-43 also contains a
C-terminal prion-like or low-complexity domain (LCD)9, mediat-
ing protein–protein interactions10 and also its incorporation into
stress granules11, potentially via its property to phase separate12, 13.
Furthermore, the TDP-43 LCD is crucially involved in disease, since
it is proteolytically cleaved and abnormally phosphorylated, leading
to its cytoplasmic accumulation in complex with the full-length
protein2, 14. Finally, TDP-43 contains an N-terminal region span-
ning its ﬁrst 80 amino acids, whose role in the function and/or
malfunction of the protein remains unclear. In fact, due to the lack
of sequence homology of this region with any known structures, the
N-terminal domain (NTD) of TDP-43 was initially thought to be
unstructured. However, it was recently reported that monomeric
TDP-43 NTD can adopt a Ubiquitin-like15 or DIshevelled and aXin
(DIX)-domain-like16 fold in solution. Intriguingly, while several
recent studies highlighted the importance of NTD for functional
TDP-43 dimerization17 and nucleic acid interaction15, 18–21, others
argued that the same domain promoted pathologic cytoplasmic
aggregation and neurotoxicity20, 22, 23. Moreover, a small fraction of
TDP-43 was reported to exist as dimers in cells, which led to
speculation that TDP-43 dimers may initiate or “seed” the forma-
tion of high molecular weight pathologic TDP-43 aggregates17.
Here, we show that physiological TDP-43 exists as nuclear
oligomers that are distinct from cytoplasmic complexes formed
upon cellular stress or pathologic aggregates. To elucidate the
molecular basis of physiological TDP-43 oligomerization,
we determined the crystal structure of TDP-43 NTD at 2.1 Å
resolution, which revealed an unprecedented mode of head-to-tail
interactions between monomers generating solenoid-like polymers.
Consistent with the crystal structure, solution NMR spectroscopy
conﬁrmed the dynamic nature of inter-molecular and low
micromolar afﬁnity electrostatic interactions that stabilize these
polymers. Destabilizing oligomerization by point mutations resul-
ted in loss of TDP-43 regulation of alternative splicing of known
neuronal RNA targets, indicating that these dynamic TDP-43
oligomers are the functional form of the protein in vivo. Tripartite
GFP complementation experiments in cells illustrate that physio-
logical TDP-43 oligomerization prevents LCD intermolecular
interactions. Importantly, we show that NTD-driven TDP-43
oligomerization antagonizes pathologic aggregation. This dynamic
head-to-tail polymerization of TDP-43, which is reminiscent of
DIX domains24 involved in Wnt signaling, is unique among RBPs
and broadens our understanding of TDP-43 function. Most
excitingly, our ﬁndings indicate that stabilization of functional
TDP-43 oligomers could have therapeutic potential by counter-
acting pathologic aggregation and restoring nuclear function.
Results
TDP-43 forms physiological oligomers in human tissues. In
order to capture the in vivo protein state, we systematically
analyzed physiological TDP-43 in cells and tissues by in situ,
chemically induced, cross-linking prior to cell/tissue lysis. For this
purpose, we used disuccinimidylglutarate (DSG), a membrane-
permeable cross-linker, which allows preservation of native
protein–protein interactions25. We performed DSG cross-linking
in normal human ﬁbroblasts and brain tissue, followed by nucleo-
cytoplasmic fractionation and immunoblotting, in order to
analyze the subcellular localization of TDP-43 oligomers and
monomers. Upon increasing the DSG concentration, a speciﬁc
ladder of slowly migrating TDP-43 complexes is detected,
consistent with increasing multimeric species of TDP-43 in
human ﬁbroblasts (Fig. 1a, Supplementary Fig. 1a–e) and human
brain (Fig. 1b, Supplementary Fig. 1f–g). The slightly different
migration pattern of TDP-43 oligomers in human motor
cortex (Supplementary Fig. 1g) is due to the different gel
(4–12% polyacrylamide) used to allow better resolution of
autopsy human brain material, which after cross-linking migrates
poorly in the regular 12% polyacrylamide gel (Fig. 1b).The higher
molecular weight TDP-43 species correspond to distinct
molecular masses of the dimer, trimer, tetramer and higher,
indicating that native cellular TDP-43 exists not only as dimers,
but rather in a spectrum of oligomeric species. The fraction of
TDP-43 present in high molecular weight oligomers is compar-
able among various samples analyzed (Supplementary Fig. 1h).
To further validate the speciﬁcity of the DSG cross-linking
protocol, we investigated the cross-linking pattern of other
hnRNPs such as hnRNPA1 and FUS that harbor similar RNA
binding and LCDs as TDP-43, but lack the NTD. For hnRNPA1,
we detect a speciﬁc dimer band predominantly in the nuclear
fractions (Supplementary Fig. 2a). However, no intermediate
oligomeric bands are detected as for TDP-43 (Fig. 1a). Interest-
ingly, for both hnRNPA1 and FUS, very high molecular weight
complexes that are unable to enter the 4–12% denaturing poly-
acrylamide gels are detected (Supplementary Fig. 2a). This is
consistent to previous reports suggesting oligomerization of
hnRNPA126 and FUS27 upon RNA binding. In contrast, wild-
type superoxide dismutase 1 (SOD1), which is known to exist
exclusively as cytoplasmic homodimers28, showed only the pre-
sence of dimeric protein without any non-speciﬁc cross-linking,
even at the highest DSG concentration used both in human
ﬁbroblasts and mouse brain slices (Supplementary Fig. 2b–c).
Multimeric TDP-43 species are detected predominantly in
the nucleus, correlating with the normal nuclear localization of
TDP-43 in healthy cells (Fig. 1a).
Nuclear TDP-43 oligomers are resistant to oxidative stress.
TDP-43 is recruited to stress granules upon oxidative stress
and forms high molecular weight complexes in non-reducing
conditions29–31. In order to determine if normal nuclear TDP-43
oligomerization is changed upon cellular stress, we treated mouse
cortico-hippocampal organotypic slice cultures with sodium
arsenite and then performed in situ cross-linking by DSG
followed by nucleo-cytoplasmic fractionation (Fig. 1c). Arsenite
induces oxidative stress by altering the redox potential in the cell.
Consistent with previously published work on cell lines29, 2 h of
arsenite treatment results in a small fraction of TDP-43 to localize
into cytoplasmic TIA-1 positive granules (white arrows in
Fig. 1d). In both control and arsenite-treated slices, the majority
of oligomeric TDP-43 resides in the nuclear fraction, suggesting
that this oligomeric state is distinct from the cytoplasmic TDP-43
pool residing in stress granule (Fig. 1e, Supplementary Fig. 2d–e).
Furthermore, nuclear TDP-43 oligomerization is independent of
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changes in the cellular redox state and is, therefore, cysteine
independent. Thus, nuclear TDP-43 oligomers are structurally
distinct from the higher molecular weight species resulting from
cysteine oxidation and disulﬁde bond formation, which are
speciﬁcally formed in response to oxidative stress, predominantly
in the cytosol30, 32.
Crystal structure of TDP-43 NTD shows superhelical packing.
Incorporation of TDP-43 in cytoplasmic stress granules is medi-
ated via its C-terminal LCD11, 22. Moreover, the nuclear localiza-
tion of TDP-43 oligomers, in conjunction with their resistance to
oxidative stress (Fig. 1c–e) suggested that nuclear TDP-43 oligo-
merization is distinct and potentially structurally independent of
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Fig. 1 TDP-43 oligomers are expressed in human cells and brain and resist oxidative stress. a Immunoblots (from 12% denaturing polyacrylamide gels) of
human ﬁbroblast fractions obtained upon incubation with increasing concentration of DSG cross-linker followed by nucleo-cytoplasmic fractionation. In the
upper panel, high molecular weight bands (marked with green asterisks) are detected with anti-human TDP-43 antibody at increasing concentrations of DSG
in the nuclear fraction (N) and in total cell lysates (T), but not in the cytoplasmic fraction (C). Lower panels show immunoblots for cytoplasmic marker
GAPDH, or nuclear marker histone H3. Immunoblots are representative of three independent experiments. b Immunoblots (from 12% denaturing
polyacrylamide gels) of human cerebellum samples. High molecular weight TDP-43 bands are detected in 1 mM DSG cross-linked samples (green asterisks)
compared to samples obtained in the absence of cross-linker. Immunoblots are representative of three independent experiments. Full immunoblots with
molecular weight marker are shown in Supplementary Fig. 1. c Schematic diagram depicting the experimental set-up for oxidative stress treatment in
mouse organotypic slice cultures followed by DSG mediated cross-linking. Subset of images (such as eppendorf tubes and microscope) in the schematic
ﬁgure were adapted from the Servier medical art (http://www.servier.com/slidekit). d Confocal microscopy images of non-treated (control) and arsenite-
treated (2 h Arsenite) mouse brain slices, immunostained with antibodies against TDP-43 and TIA-1. Cytoplasmic TDP-43 granules (red) co-localize with
the stress-granule marker TIA-1 (green). Merged images including DAPI-staining of nuclei (blue) are shown in the right panels. e Immunoblots (from 12%
denaturing polyacrylamide gels) of control (NT) and arsenite-treated (As) mouse brain slices after cross-linking by DSG and nucleo-cytoplasmic
fractionation. DSG-cross-linked oligomeric TDP-43 (marked with green asterisks) remains localized in the nuclear fraction after oxidative stress.
Immunoblots are representative of three independent experiments
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LCD. We, therefore, focused on the NTD of TDP-43, whose role in
protein dimerization was previously suggested18, 19.
In order to understand the molecular basis of TDP-43
oligomerization, we aimed at determining a high-resolution
structure of TDP-43 NTD. Based on the previously reported
domain boundaries15, 16, we expressed and puriﬁed recombinant
human TDP-43 NTD (amino acids 1–80) in amounts amenable
for structural analysis (Fig. 2a, Supplementary Fig. 3a). TDP-43
NTD was puriﬁed under native conditions, without the use of any
denaturant during the puriﬁcation process, in contrast to earlier
reports where some denaturants (such as urea) were included that
may lead to destabilization of oligomers in solution15, 16.
Subsequently, vapor diffusion crystallization experiments of
puriﬁed recombinant protein were set up that led to initial
crystallization hits. These small crystals were used for microseed-
ing experiments to grow larger crystals (70 × 70 × 200 μm) that
diffracted to 2.1 Å resolution (Supplementary Fig. 3b, Table 1).
Initial molecular replacement trials using the deposited TDP-43
NTD NMR structure16 (PDB ID code 2N4P) failed. However,
crystals were grown in sodium cacodylate buffer and consequently
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Fig. 2 Crystal structure of TDP-43 NTD at 2.1 Å resolution. a Schematic domain organization of human TDP-43 with the N-terminal domain (NTD) shown
in blue, RNA recognition motifs (RRMs) in gray and the low-complexity domain (LCD) in red with domain boundaries indicated on top. b Crystals of TDP-43
NTD show helical ﬁlaments with single molecules arranged in head-to-tail fashion as seen from the side. Atoms of Mol-A and -B (comprising asymmetric
unit) are shown as cyan and blue spheres, respectively. The dimensions of the crystallographic helix are indicated. c Wall-eyed stereo view of two TDP-43
NTD molecules (Mol-A, Mol-B) in the asymmetric unit. The two molecules are shown in cartoon representation with the secondary structure elements and
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starting phases were obtained by single-wavelength anomalous
dispersion making use of the strong anomalous signal that was
generated by the arsenic K-edge (Table 1). Using the anomalous
signal, we obtained a substructure with four cacodylate ions that
were covalently bound to surface exposed cysteine residues.
TDP-43 NTD crystallized in space group P63 and two
molecules (Mol-A, Mol-B) are found in the asymmetric
unit, whose structures are virtually identical, indicated by a root-
mean square deviation (r.m.s.d) of 0.612 Å (Cα atoms of residues
1–80). Crystallographic symmetry generated three intertwined
superhelices of TDP-43 NTDs packed against each other, building
a tubular superstructure (Supplementary Fig. 3c, d). Each of these
tubules is surrounded by another six tubules, thereby forming the
lateral contacts of the crystal. Within each superhelix, every turn is
composed of 12 TDP-43 NTD monomers (two molecules per
asymmetric unit) with a rise of 24.6 Å between two asymmetric
units, a helical pitch of 147.6 Å and a radius of 34 Å to the center
of mass, respectively, (Fig. 2b).
Head-to-tail interaction of TDP-43 NTD monomers. Except for
the N-terminal His-tag, all other residues were well resolved in the
ﬁnal electron density map. The structure of the TDP-43 NTD
monomer is similar to the previously reported NMR structure with
a global r.m.s.d of 1.97 Å for Mol-A and 2.12 Å for Mol-B for Cα
atoms (Supplementary Fig. 3e), explaining the failure of solving the
structure by molecular replacement. Signiﬁcant differences are seen
in the orientation and conformation of loops, especially the β3-β4
loop that seems to be ﬂexible based on the NMR data16, however, it
is involved in inter-molecular interactions between monomers in
the crystal structure (Fig. 2c, Supplementary Fig. 3f). TDP-43 NTD
adopts a compact fold comprised of a ﬁve-stranded β-sheet (β2-β1-
β5-β3-β4) packing against one α-helix (Fig. 2c). An additional
β-hairpin is present in the loop between β4- and β5-strands (βa
and βb in Fig. 2c). Such domain architecture is reminiscent of
Ubiquitin and DIX domains (see Discussion).
The inter-molecular interface between consecutive monomers
is conferred by two distinct regions in the protein. The head
region (on the right when viewing the β-sheet with the β1-strand
pointing up) of TDP-43 NTD is positively charged and
interactions are made by residues mainly from β3- (Asn45),
β4- (Arg52, Arg55), β5- (Asn76) strands and the β3-β4 loop
(Ser48) (Fig. 2c, d). In contrast, the tail (on the left, viewing from
β-sheet with β1-strand going up) of the molecule is negatively
charged (Fig. 2e) and is comprised of residues from the
β2- (Glu17) strand, the α1-helix (Gln34) and the β1-β2 (Glu14)
and β2-α1 (Glu21) loops that interact with the adjacent molecule
(Fig. 2c, e). Such interaction between NTD molecules results in
charge complementation. In addition, at each interface,
β2-strand of one monomer forms a parallel inter-molecular
β-bridge with the β4-strand of the adjacent monomer in which
the main chain atoms of Glu17 (β2-strand) forms H-bonds with
the backbone of Met51 and Gly53 (β4-strand) (Fig. 2c,
Supplementary Fig. 4a, b). This interaction is strengthened by the
guanidinium groups of Arg55 and Arg52 that form salt bridges
with the carboxyl groups of Glu21 and Glu17, respectively
(Fig. 2c, Supplementary Figs. 4b and 5a, b). Additionally,
the carboxyl group of Glu17 forms speciﬁc hydrogen bonds
with the hydroxyl group of Ser48 and the carboxamide group of
Asn45 (Fig. 2c, Supplementary Figs. 4b and 5a). Moreover,
the aliphatic side chains of Ile16 and Pro19 (in Mol-B) interact
with the aliphatic parts of side chains of Met51, Arg52, and
Arg55 (in Mol-A), respectively, to create a small hydrophobic
contact at the interface (Fig. 2c, Supplementary Fig. 4b).
Finally, the α1-helix of one monomer packs against the β-sheet
of the other molecule where in the carboxamide of Gln34
(α1-helix) makes hydrogen bonds to the carboxamide nitrogen of
Asn76 (β5-strand) and the backbone carbonyl oxygen of Leu41
(β3-strand) (Fig. 2c, Supplementary Figs. 4a and 5c).
Thus, the two NTD molecules in the asymmetric unit interact
extensively with one another in head-to-tail fashion (Fig. 2c,
Supplementary Fig. 3f), burying a total surface area of 644.2 Å2 at
the interface between Mol-A and Mol-B within the asymmetric
unit and 648.1 Å2 between Mol-B and Mol-A’ between two
adjacent asymmetric units (the prime refers to a molecule related
by crystallographic symmetry). This area is comparable to the
buried surface area in the oligomeric structures formed by the
DIX domains of both Axin-1 (768 Å2) and Dishevelled Segment
Polarity Protein-2 (425–470 Å2).
Dynamic polymerization of TDP-43 NTD revealed by NMR. In
order to conﬁrm and validate the interactions observed in the
crystal structure, we utilized NMR spectroscopy. At 50 μM
protein concentration, isotopically labeled TDP-43 NTD appears
to be clearly folded in solution as indicated by the wide NMR
chemical shift dispersion in the two-dimensional (2D) 1H-15N
Heteronuclear Single Quantum Coherence (HSQC) spectrum
(Fig. 3a). Interestingly, upon increasing the protein concentration,
a subset of cross peaks of TDP-43 NTD undergoes chemical
shift perturbations (CSPs) and increased spectral line widths
(Fig. 3a). Sequence-speciﬁc resonance assignments of TDP-43
NTD (Supplementary Fig. 5d) revealed that these perturbations
are mainly corresponding to residues I18 (in β2-strand),Val31,
Thr32, Ala33, and Gln34 (in α1-helix), Cys39, Gly40 and Asn45
(in β3-strand), Arg52 and Gly53 (in β4-strand) and Val75 and
Table 1 Data collection and reﬁnement statistics
TDP-43 NTD
Data collection
Space group P63
Cell dimensions
a, b, c (Å) 89.52, 89.52, 49.15
α, β, γ (°) 90, 90, 120
Resolution (Å) 44.76–2.10 (2.15–2.10)
Rmeas 0.108 (2.03)
Rmerge 0.103 (1.94)
I/σI 16.7 (1.6)
CC1/2 1.00 (0.59)
Completeness (%) 98.8 (100.0)
Redundancy 10.41 (10.92)
Δano/ σΔano 1.3 (0.7)
Reﬁnement
Resolution (Å) 49.15–2.10
No. of reﬂections 12,500
Rwork/Rfree 0.166/0.206
No. of atoms 1344
Protein 1192
Ligand/ion
Acetate 1
Cacodylate 4
Water 108
B-factors
Protein 48.46
Ligand/ion 54.16
Water 56.2
R.m.s. deviations
Bond lengths (Å) 0.031
Bond angles (°) 2.72
One crystal was used for data collection. Values in parentheses are for the highest-resolution
shell. Friedel pairs were treated as different reﬂections due to the signiﬁcant anomalous signal.
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Asn76 (in β5-strand, Fig. 3a). These are fully consistent with the
inter-molecular interface seen in the crystal structure (Fig. 3b).
Furthermore, Gly53, which is involved in an inter-molecular
β-bridge, shows signiﬁcant line broadening that goes beyond
detection at higher protein concentrations (green circle in
Fig. 3a). Interestingly, this process is reversible because upon
dilution the cross-peaks become narrower and shift back to
their original position showing that this oligomerization of
TDP-43 NTD is dynamic in solution. The CSPs are in fast to
intermediate exchange regime on the NMR time scale and the
concentration dependence range implies that the afﬁnity of NTD
monomer self-association is in the low micromolar range, which
is comparable to the reported dissociation constant for DIX, Phox
and Bem1 (PB1) domains (5–20 μM for Axin-1, 200 μM for Axin-
1-Dvl-2 and 100 μM for Par-3-PB1 domain)33–35.
Visualization of polymeric TDP-43 NTD by electron microscopy.
To directly visualize the TDP-43 NTD polymers under native
conditions, we used transmission electron microscopy (TEM) on
negatively stained samples of puriﬁed recombinant protein in the
buffer conditions used for NMR experiments. TDP-43 NTD
formed ﬁbrillar structures of variable length and diameter, even at
low protein concentrations of 100 μM (Fig. 4a). Some ﬁlaments
are about 7 nm in diameter, which corresponds to the width of
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the helical ﬁlament seen in the crystal structure, while the
observed thicker ﬁlaments may result from coalescence of indi-
vidual ﬁlaments. Taken together, the head-to-tail interaction
interface seen in the crystal structure and conﬁrmed in solution
by NMR and the ability of TDP-43 NTD to form ﬁbrillar
structures in native buffer may explain the intrinsic
oligomerization property of TDP-43 seen in vivo (Fig. 1a, b). The
negatively charged tail (Glu14, Glu17, and Glu21) and the posi-
tively charged head (Arg52 and Arg55) interaction interface are
evolutionary conserved (Supplementary Fig. 6a), suggesting a
conserved mode of TDP-43 oligomerization across various
species.
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Interface disrupting mutations abolish TDP-43 polymerization.
In order to investigate the functional relevance of the interaction
interface observed in the crystal structure and in solution, we
designed, expressed and puriﬁed recombinant proteins with
speciﬁc point mutations that disrupt the oligomerization interface
(Fig. 4b, Supplementary Fig. 6b–c), without affecting the folded
state of the protein (Fig. 4c, Supplementary Fig. 6d). Based on the
crystal structure, interference with one charged surface should be
sufﬁcient to prevent protein oligomerization in vitro. Indeed, both
the double mutant E17A/E21A in the tail region (Tm) and R52A/
R55A in the head region (Hm) and different combinations of head
and tail mutants (designated 4, 5, and 6M; Supplementary Fig. 6b)
abolish oligomerization of the protein in vitro, as monitored by
NMR spectroscopy and TEM (Fig. 4d, e, Supplementary
Fig. 7a–d). Signiﬁcant changes in the 2D 1H-15NHSQC spectra of
mutant proteins compared to wild-type NTD occurred, due to
disruption of the interaction interface (Fig. 4c, Supplementary
Fig. 6d). Furthermore, the narrow and uniform spectral line
widths of mutant proteins compared to the wild type protein,
remaining at even higher protein concentrations (800 μM)
(Fig. 4d) strongly suggested their monomeric nature in solution.
Most importantly, no changes in chemical shifts were observed
upon increasing protein concentration of isotopically labeled
mutant proteins (Fig. 4d, middle panel in Supplementary
Fig. 7a–d). Additionally, as analyzed by electron microscopy, none
of the mutant TDP-43 NTD formed any ﬁbrils but predominantly
formed amorphous deposits in the supporting matrix used in the
TEM studies (Fig. 4e, right panel in Supplementary Fig. 7a–d).
To investigate the role of NTD-driven TDP-43 oligomerization
in cells, we introduced interface-disrupting point mutations in the
context of GFP-tagged full-length human TDP-43 in mouse
motor neuron-like NSC-34 cells. To prevent oligomerization of
overexpressed protein with endogenous mouse TDP-43, which is
96% identical to human TDP-43, we used point mutations in
both head and the tail region (mutants designated 4, 5, and 6M;
Fig. 4b, Supplementary Fig. 6b). Oligomerization of transiently
expressed protein was analyzed following DSG cross-linking in
cells. The mutations severely abrogate the ability of overexpressed
protein to form higher molecular weight TDP-43 oligomers with
most severe disruption of oligomerization observed in TDP-43-
6M, where both head and tail regions are mutated simultaneously
(Fig. 4f, Supplementary Fig. 7e). These data suggest that cellular,
full-length TDP-43 oligomerizes via its NTD utilizing the same
protein–protein interface identiﬁed in the crystal structure and
solution studies.
TDP-43 polymerization is crucial for RNA splicing regulation.
TDP-43 has been shown to regulate splicing of speciﬁc RNA targets
by binding to proximal intron-exon junctions of pre-mRNA6, 36, 37.
Indeed, TDP-43 downregulation in mouse brain resulted in
characteristic splicing alterations of target mRNAs6. To validate the
inter-molecular interactions seen in the crystal structure and assess
their functional importance, we analyzed the ability of oligomer-
ization mutants to rescue the splicing defects induced by endogen-
ous TDP-43 depletion in mouse NSC-34 cells (Fig. 5a). We
employed a previously reported TDP-43-speciﬁc siRNA38, which
reduced endogenous mouse TDP-43 levels by > 90%, without
interfering with expression of co-transfected RNAi-resistant wild-
type or oligomerization-deﬁcient human TDP-43 mutants (Fig. 5b).
RNAi resistance was accomplished by scrambling the TDP-43 target
sequence of siRNA, without altering the coded protein sequence.
Transiently expressed wild-type and oligomerization-deﬁcient TDP-
43 proteins showed similar expression levels and cellular localization
both in the nucleus and the cytoplasm of transfected cells (Supple-
mentary Fig. 8a–g), allowing a comparison in their ability to rescue
the RNA splicing function in the nucleus. Consistent with our
previous ﬁndings6, downregulation of TDP-43 resulted in misspli-
cing of speciﬁc RNA targets, such as Sort1 (Sortilin1), Dnajc5 (DnaJ
homolog subfamily C member 5), Poldip3 (polymerase delta-
interacting protein 3), Eif4h (eukaryotic translation initiation factor
4H), Sema3 (semaphorin-3F), and Tsn (translin), which was rescued
by co-transfection with wild type TDP-43 (Fig. 5c). In contrast, the
oligomerization-deﬁcient mutants failed to rescue RNA missplicing,
strongly indicating that head-to-tail NTD-driven TDP-43 oligo-
merization is essential for its function in RNA splicing. We observed
a similar pattern in rescuing splicing defect in Adnp2 that has been
reported to express a cryptic exon upon TDP-43 downregulation39
(Fig. 5c). As a negative control, we assessed the splicing pattern of
App, which is a direct RNA target of TDP-43, but whose splicing is
not regulated by TDP-436. Additionally, point mutations away from
the oligomerization interface could rescue the splicing defect similar
to wild type TDP-43 (Supplementary Fig. 9a–c). Furthermore,
consistent with in vitro experiments (Fig. 4f, Supplementary Fig. 7a,
b), mutation of only two residues (one charged interface) is sufﬁcient
to abolish the function of TDP-43 in splicing, highlighting their
role in the oligomerization-dependent function of the protein
(Supplementary Fig. 9d, Supplementary Fig. 10a–h).
Dynamic TDP-43 polymerization impedes pathologic aggregation.
Based on our structural and functional data, we hypothesized that
the NTD-mediated, dynamic, physiological oligomerization might
orient the LCDs of two adjoining TDP-43 molecules within the
oligomer apart from each other. Such orientation would prevent
inter-molecular LCD interactions and might potentially antagonize
irreversible protein aggregation and phosphorylation. To experi-
mentally test this and determine the relative spatial location of
N- and C-terminal regions of adjacent TDP-43 molecules within
oligomers, we used the tripartite split GFP complementation sys-
tem40 in mouse immortalized multipotent neural progenitor C17.2
cells (Fig. 6a). For this, we tagged either the N- or the C-termini of
Fig. 5 TDP-43 oligomerization is essential for its role in RNA metabolism. a Schematic overview of rescue experiment to assess the role of TDP-43
oligomerization in RNA splicing. Point mutations interfering with TDP-43 oligomerization are schematically marked by red asterisks below the NTD.
b Immunoblot (from 12% denaturing polyacrylamide gel) using an antibody against mouse/human TDP-43, showing speciﬁc downregulation of endogenous
mouse TDP-43 and overexpression of RNAi resistant GFP-tagged wild type and oligomerization mutant human TDP-43 (GFP-TDP-43-4M/5M/6M) in
mouse NSC-34 cells (upper panel). Actin is used as protein loading control (lower panel). Immunoblots are representative of four independent experiments.
c Semi-quantitative RT-PCR analysis of selected target’s alternative splicing regulated by TDP-43. Left panel depicts alternatively spliced exons (orange) or
cryptic exons (red) ﬂanked by their constitutive exons in blue boxes. Middle panel shows representative polyacrylamide gel images of semi-quantitative
RT-PCR products for all conditions. Right panel shows quantiﬁcation of splicing changes plotted as the ratio of exon inclusion/exclusion (on y-axis) against
different conditions (on x-axis) averaged from four biological replicates and normalized to the ratio obtained for not treated (NT) cells that is arbitrarily set to
1. In all cases, the expression of wild-type TDP-43 (green bars) rescues the changes in splicing caused by downregulation of endogenous mouse TDP-43
(TDP-43 si-RNA, black bars). The effect of each oligomerization mutant TDP-43 is shown (red bars). Statistical comparison of the inclusion/exclusion ratio
between wild type and oligomerization mutants (4M, 5M, or 6M) is indicated by asterisks above respective bars (*p< 0.05, **p< 0.01, ***p< 0.001, two-
tailed Student t-test). Standard deviation is represented by error bars. Full gels with molecular weight markers are shown in Supplementary Fig. 10
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TDP-43 with the 10th (T10) or the 11th (T11) β-strand of GFP,
which when in close proximity to each other can reconstitute
ﬂuorescence of the remaining GFP1–9 protein, which by itself lacks
ﬂuorescence ability40 (Fig. 6a). We observed ﬂuorescence recon-
stitution with GFP1–9 only when T10/T11 were both positioned at the
N-terminus of TDP-43 (T10/T11-TDP-43, Fig. 6b), but not at the C-
terminus (TDP-43-T10/T11, Fig. 6c), or any other N- or C-terminal
combinations (Supplementary Fig. 11a). These data indicate that
indeed the C-termini of the adjoining molecules within TDP-43
oligomers are distantly located from each other, as opposed to the
N-termini that comprise the oligomerization interface within cells.
To rule out the loss of ﬂuorescence reconstitution due to
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inaccessibility of the TDP-43 C-terminal region, we co-transfected
either the N- or C-terminal T10/T11 TDP-43 with GFP1–10, which
conﬁrmed complementation of T11-tagged TDP-43, independently
of its fusion site (Supplementary Fig. 11b–d). This suggests, that a
lack of ﬂuorescence reconstitution with GFP1–9 at C-terminally
tagged T10/T11 is indeed due to distant spatial organization of the
TDP-43 C-termini in the cellular oligomers.
Collectively, the above data conﬁrms that nuclear and functional
TDP-43 oligomerization is formed via the interaction of its NTD
and that within these oligomers the C-terminal LCDs of adjoining
molecules are spatially separated. Since LCD interactions are
necessary for cytoplasmic TDP-43 accumulation14, 29, we reasoned
that NTD-mediated oligomerization may antagonize its aggrega-
tion. To test this hypothesis, we compared the ability of wild-type
and oligomerization-deﬁcient TDP-43 to be recruited into
cytoplasmic phosphorylated TDP-43 inclusions. Following tran-
sient overexpression of human GFP-tagged TDP-43, a small
fraction of NSC-34 cells develop cytoplasmic aggregates that
become abnormally phosphorylated, reminiscent to the character-
istic pathology found in sporadic ALS patient tissue2. While image
analysis of over 2500 control cells—either non-transfected, or GFP-
transfected—failed to detect any phosphorylated TDP-43 signal,
~ 15–20% of wild type TDP-43-expressing cells showed phos-
phorylated TDP-43 inclusions, potentially driven by overexpres-
sion and increased cytoplasmic concentration of the nucleo-
cytoplasmic shuttling protein (Fig. 6d, Supplementary Fig. 12).
Remarkably, the percentage of cells showing cytoplasmic phospho-
TDP-43 aggregates is signiﬁcantly and consistently higher in both
oligomerization-defective mutants (TDP-43-6M and TDP-43-
ΔNTD), compared to wild type (Figs. 6e–g), suggesting an
increased propensity of oligomerization mutants to form cyto-
plasmic aggregates. To test for increased aggregation in oligomer-
ization mutants, we performed sequential insolubility assay (SIA)
exposing the cell lysates to detergents of increasing strength
(Supplementary Fig. 13a). Consistent with increased pTDP-43 in
oligomerization mutants, the mutant protein also shows enhanced
insolubility compared to the wild type, reﬂecting its enhanced
tendency to aggregate (Supplementary Fig. 13b, c).
In conclusion, our high-resolution structural, biochemical, and
cellular analyses uncover a novel NTD-mediated dynamic and
functional TDP-43 oligomerization, which antagonizes its
irreversible pathologic cytoplasmic aggregation.
Discussion
TDP-43 is a multifunctional and essential RBP, whose abnormal
cytoplasmic misaccumulation is integrally linked to the patho-
genesis of ALS and FTD1, 2. In this study, we provide evidence
that the physiological TDP-43 state in the nucleus is oligomeric
and that this oligomerization is indispensable for the functional
role of the protein in RNA metabolism. Dimerization or
oligomerization of RBPs can occur in an RNA-dependent or
independent fashion41. Our crystal structure shows that
NTD-driven TDP-43 oligomerization is independent from RNA
binding, although the potential increase in local TDP-43
concentration upon RNA binding within cells may well favor
oligomerization. Nevertheless, oligomeric TDP-43 would be
expected to increase both its afﬁnity and speciﬁcity for its RNA
targets, compared to a monomeric form. This is in agreement
with the observation from our previous CLIP-seq data in mouse
brain6, showing that in most TDP-43 RNA targets, the
UG-repeats are longer than required for binding of TDP-43
monomer, whose “footprint” on RNA comprises of 3–4 UG
repeats6. In fact, 63% of total TDP-43-binding sites identiﬁed by
CLIP-seq occur within long intronic regions and this binding
sustains the levels of RNAs important for neuronal function6. An
attractive hypothesis that emerges from our current study is that
TDP-43 binds these regions preferentially as an oligomer to
increase afﬁnity towards long contiguous UG-repeats. Direct
RNA binding of the NTD may contribute to this, as suggested by
the low afﬁnity binding of this domain to TG repeats by gel shift
assay (Supplementary Fig. 14a), consistent with previous
reports18 showing some—albeit low—contribution of TDP-43
NTD to RNA binding. Moreover, TDP-43 oligomerization may
act as a “recruitment platform” for speciﬁc factors involved in
splicing and RNA maturation steps important for sustaining their
levels. Another potential role of NTD-driven inter-molecular
TDP-43 interaction is the ability to bring distal sites on RNA in
close proximity, resulting in looping-out of RNA. Depending on
the binding sites, this mechanism may promote inclusion or
skipping of alternative exons. Such a mechanism has previously
been proposed for other RBPs such as PTB42, hnRNP A/B,
hnRNP F/H43, and STAR proteins (T-star and Sam68)44.
TDP-43 oligomerization is novel and unique among the higher
order structures described for other RBPs and is mediated by
NTD, whose structural homologs have not been reported in any
other RBP until now. However, a sub-set of protein–protein
interaction domains such as DIX, PB1, and sterile alpha motif
(SAM) domains undergo similar head-to-tail interactions to
generate not only homo- but also heteropolymers that have been
implicated in modulating signalosome assembly24. Interestingly,
despite very low sequence homology (Fig. 7a), TDP-43 NTD
displays high structural similarity with both the monomer
structure (Supplementary Fig. 14b), and the polymer structure of
DIX domains (Fig. 7b, Supplementary Fig. 14c–e), while only
resembling the monomeric structure of ubiquitin as proposed
earlier15. However, while the interaction interface is comprised of
similarly positioned structural elements in DIX domains, the
molecular interactions are different in TDP-43 NTD (Fig. 7a).
Nevertheless, based on high structural resemblance to DIX
domains, it is conceivable that TDP-43 NTD might as well
modulate speciﬁc signaling events by regulating the high local
concentration of the protein. Interestingly, TDP-43 has been
shown to interact with the signaling molecule nuclear factor
(NF)-κB subunit p65 via its NTD38 and it would be important to
clarify if this interaction depends on TDP-43 oligomerization.
Fig. 7 Novel TDP-43 oligomerization domain and implications for disease. aMultiple sequence alignment of TDP-43 NTD with structurally homologous DIX
domains (Axin-1, Dvl-2) and Ubiquitin. Alignment was performed by T-coffee (http://www.ebi.ac.uk/Tools/msa/tcoffee/) and the alignment ﬁgure was
generated in Jalview (http://www.jalview.org/). TDP-43 NTD secondary structural elements are depicted above the sequence and residues involved in the
inter-molecular interactions within TDP-43 NTD are marked by red asterisks below the sequence. Sequence conservation scores are shown below the
alignment as color gradient (dark yellow—poor conservation, light yellow—high conservation). b Overlay of structures of TDP-43 NTD (in blue) with Axin-1
DIX (in magenta, PDB ID 1WSP), Dvl2-DIX (in green, PDB ID 4WIP), and Ubiquitin (in yellow, PDB ID 1TBE). Structures are overlaid on one molecule to reveal
the differences in the orientation of the second molecule. Individual structures in the same orientation are shown around the overlay. c Role of dynamic
nuclear TDP-43 polymerization in physiological conditions and in disease. Within the nucleus, TDP-43 oligomerizes via the NTD and such conformation
prevents irreversible aggregation by spatially separating the LCDs of adjoining TDP-43 molecules. Disturbance in the equilibrium between the oligomeric and
monomeric TDP-43 in the cytoplasm (shown by green-red arrows) may result in proteolytic cleavage of exposed monomeric TDP-43 and generation of C-
terminal fragments lacking the NTD. These highly aggregative fragments may initiate formation of irreversible pathologic inclusions via the LCD
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The mechanism of transition of physiological nuclear TDP-43 to
pathologic, irreversible and insoluble protein assemblies remains
enigmatic, but it is likely triggered by the proteolytic release of
its C-terminal LCD, which harbors most of the ALS-linked
mutations1 and possesses high propensity to self-associate11, 29,
phase separate12, 13, and aggregate2. Our current data strongly
support the hypothesis that formation of physiological NTD-
mediated, nuclear TDP-43 oligomers can counteract cytoplasmic
aggregation (Fig. 7c). Any factor altering the cellular equilibrium
between oligomeric and monomeric TDP-43 may trigger the
initiation of cytoplasmic TDP-43 aggregation (Fig. 7c). It is
conceivable that the NTD-driven oligomeric state protects TDP-43
from proteolytic cleavage, a process characteristic for pathologic
TDP-43 in ALS patients2. Such cleavage, releases TDP-43 LCD,
which no longer possesses the ability to form dynamic oligomers
due to lack of the essential NTD. Therefore, TDP-43 LCD can act
as a potent “seed” to trigger the formation of pathologic TDP-43
aggregates, which are comprised of both full-length and C-terminal
TDP-43 fragments in ALS patients2 (Fig. 7c).
Finally, although the relative contribution of loss of normal nuclear
TDP-43 function and gain of toxicity of its cytoplasmic aggregates
remains unknown, a combinatorial mechanism may well operate in
disease, which precludes many possibilities for interventions that
target either loss or gain of function exclusively. We propose that
stabilizing TDP-43 functional oligomers could be an attractive ther-
apeutic strategy to counteract irreversible cytoplasmic TDP-43
aggregation, while preserving its normal nuclear function.
Methods
Human samples. Frozen autopsy samples of non-neurological control human
cerebellum and motor cortex were provided by Dr John Ravits from University of
California, San Diego and all patient consent was taken in the clinics.
Cross-linking in cells and tissues. Cross-linking in cells and tissues was
performed by using DSG25, which is a membrane permeable molecule that can
passively diffuse inside living cells. DSG stabilizes native protein–protein interac-
tions by forming irreversible covalent bonds between primary amine groups in the
proteins. For cross-linking in cells, mouse NSC-34 and human ﬁbroblasts were ﬁrst
harvested using trypsin (Gibco) and its subsequent inhibition by Trypsin inhibitor
(Gibco). The cells were washed twice with phosphate-buffered saline (PBS, pH 7.4)
and then resuspended in 100 μL PBS. Fresh 20 mM DSG (Sigma) stocks were
prepared in dimethylsulphoxide. The reaction was started by adding an appropriate
volume of the DSG stock to the 100 μL cell suspension (with Roche protease
inhibitor cocktail in PBS) at a ﬁnal DSG concentration of 50, 100, 250, 500, and
1000 μM. The reaction was incubated at room temperature with shaking for 30 min
and then quenched by addition of Tris base (at a ﬁnal concentration of 20 mM) for
15 min at room temperature (RT).
For cross-linking in human and mouse brain (frozen, post-mortem human
cerebellum, motor cortex, and mouse organotypic slices), tissue samples were
chopped twice on a Tissue Chopper (McIlwain Tissue Chopper, setting blade
distance to 100 μm). In between each chopping, the sample was rotated by 90° to
ensure ﬁne mincing of the brain tissue. The ﬁnely minced brain samples were then
transferred to 15mL polypropylene tubes (GreinerBio-One)and resuspended in 5mL
PBS/PI by gentle pipetting (3–4 times). From this tissue suspension, homogeneous
aliquots were transferred to 1.5mL eppendorf tubes (Protein LoBind, Eppendorf),
that were centrifuged at 1500xg for 5 min at RT. Supernatants were rejected, and the
pellets underwent cross-linking by addition of 1000 μL of 1 mM DSG in PBS/PI for
100mg tissue. The samples were incubated at 37 °C for 30min with shaking followed
by quenching with 20mM Tris base (ﬁnal concentration) for 15min.
Nucleo-cytoplasmic fractionation. Intact cell pellet or human and mouse tissue
pellet following cross-linking were lysed in lysis buffer (50mM Tris pH 7.4, 10mM
NaCl, 0.5% NP-40, 0.25% TritonX-100, 1mM EDTA, protease inhibitors (Roche)) by
incubating 5min on ice37. After centrifugation at 3000xg for 5min at 4 °C, the
supernatant was collected as the cytoplasmic fraction and the pellet as the nuclear
fraction.
Oxidative stress treatment on mouse brain slices. Three-hundred ﬁfty
micrometer thick brain slices were prepared from 5–8 day old C57BL/6J pups
according to previously published protocols modiﬁed for cortico-hippocampal
slices45. Two slices each were cultured in Millicell-CM inserts (Millipore) in
forebrain culture medium (50% BME, 25% Earle’s salt solution, 25% heat
inactivated horse serum, supplemented with 1% glucose, penicillin/streptomycin,
and Glutamax (Invitrogen)). Slice cultures were kept in culture for 3 weeks (37 °C,
5% CO2, and 95% humidity) before the start of the experiment to stabilize them
after the cutting procedure. To induce oxidative stress, 0.25 mM sodium (meta)
arsenite (Sigma) was added to the medium for 2 h. For crosslinking experiments,
slices were subsequently scraped into PBS and a homogenous cell suspension was
prepared by pipetting up and down. The cross-linking procedure was performed as
described above with 1 mM DSG. Anti-TDP-43 antibody (Bethyl, Supplementary
Table 1) was used for immunoblotting. For immunoﬂuorescence imaging, slices
were washed in PBS, ﬁxed in 4% paraformaldehyde, blocked for 4 h with blocking
buffer (10% donkey serum (DS), 0.3% Triton-X) and stained using anti-TDP-43
antibody (Proteintech, Supplementary Table 1), and anti-TIA-1 antibody
(Santa Cruz, Supplementary Table 1) for 3 days. In all, 488- and 594-Alexa
Fluor-conjugated secondary antibodies raised in donkey (Life technologies) were
used (2 days incubation). Nuclei were stained with 4,6-diamidino-2-phenylindole
(DAPI) and slices were mounted in ﬂuorescent anti-fade mounting medium
(Life technologies). Images were taken with an inverse confocal microscope
(Leica DMI6000B, SP5) in the middle of the slice tissue.
Protein expression and puriﬁcation. For bacterial recombinant protein expres-
sion, the DNA nucleotide sequence coding for full-length human TDP-43 (414
amino acids) was PCR ampliﬁed and cloned into the expression vector—pET-28a
(+). Subsequently, the region corresponding to the NTD (amino acids 1–80) was
sub-cloned into the pET28a(+) expression vector. Point mutations were incorpo-
rated by site-directed mutagenesis PCR using high ﬁdelity Phusion DNA
Polymerase (New England biolabs) with primers introducing DNA base substitu-
tions (Supplementary Table 3). The protein was overexpressed in Escherichia coli
host cells BL21 codon plus RIL strain (Agilent, Catalog number #230240). Bacterial
cultures were induced at OD600= 1.0 by adding 1 mM isopropyl β-D-thiogalacto-
side (IPTG, Sigma) at 25 °C for 30 h in minimal M9 medium containing 15NH4Cl
as nitrogen source and/or 13C-D-glucose as a carbon source for labeled protein
samples. For unlabeled protein samples, bacterial cultures were grown in Luria-
Bertani (LB) medium (Invitrogen). Following cell harvesting, the cell pellets
were resuspended in lysis buffer that comprised of 50 mM sodium phosphate,
pH 8.0, 300 mM NaCl, 10 mM imidazole, 1 mM dithiothreitol (DTT), 1 mM
phenylmethylsulphonyl ﬂuoride. Cell pellets were resuspended in 20 mL of lysis
buffer per liter of bacterial culture pellet. The resuspended cells were then lysed by
microﬂuidizer. Total cell lysates were then centrifuged (Sorvall SS-34 rotor,
45,000xg, 40 min). Pellet was discarded and the supernatant containing soluble
protein was used for further puriﬁcation. Protein puriﬁcation was achieved on
ÄKTA Prime puriﬁcation system (Amersham Biosciences) where the N-terminal
His-tagged protein was puriﬁed with Ni2+-afﬁnity chromatography under native
conditions. The bound protein was eluted from Ni2+-columns using a linear
gradient of imidazole in elution buffer (50 mM sodium phosphate, pH 8.0,
1 M NaCl, 500 mM imidazole, 1 mM DTT). The fractions containing pure protein
(analyzed on SDS polyacrylamide gel electrophoresis) were pooled and dialyzed
overnight in a buffer without imidazole (5 mM sodium phosphate, pH 7.4, 1 mM
NaCl, 1 mM DTT). Finally, the protein was concentrated using a Vivaspin 5000
MWCO concentrator (Sartorius Stedium Biotech). Further protein puriﬁcation
was achieved by size exclusion chromatography using a Superdex75 column
(GE Healthcare). The puriﬁed protein was aliquoted and stored at −20 °C.
Crystallization and data collection. To screen for initial crystallization
conditions, commercially available sparse matrix screens from Hampton
Research (Hampton Research, California, USA) and Molecular Dimensions
(Molecular Dimensions, Suffolk, UK) were used to set up sitting-drop vapor
diffusion experiments. For this, puriﬁed protein at a concentration of 10 mgmL−1
was mixed in a 3:1 (protein:mother liquor) ratio, dispersed on a 96 well Intelli-Plate
96-3 LVR crystallization plate (Art Robbins) using a Phoenix crystallization robot
(Art Robbins) and incubated at 4 °C against 50 µL reservoir solution. An initial
crystallization hit was found in 50 mM Tris/HCl pH 8.5, 8%(w/v) PEG 8000. These
crystals were crushed and used for matrix microseeding in Crystal Screen 1&2 from
Hampton Research (Hampton Research, California, USA). This led to new crystals
in 0.1 M sodium cacodylate pH 6.5 and 1.4 M sodium acetate and a ﬁne screen with
differing pH and molarity of the sodium acetate was set-up, which resulted in
crystals with good diffraction quality.
For data collection, crystals were incubated in mother liquor containing 30%
ethylene glycol and ﬂash-cooled in liquid nitrogen. Data were collected at beamline
X06DA at the Swiss Light Source (PSI, Villigen, Switzerland) with a wavelength of
1 Å using the PILATUS 2M-F detector system (Dectris, Switzerland) and processed
with XDS46. Due to the formation of weak ice-rings, data between 2.235 and 2.245
Å resolution were excluded. The outer resolution limit was estimated using the
CC1/247 and I/σ(I) criteria48. According to these criteria diffraction data were cut
at 2.1 Å resolution with CC1/2 and I/σ(I) of 59.2% and 1.6% in the outer resolution
shell, respectively.
Structure determination and reﬁnement and analysis. Using the anomalous
signal from the dimethyl arsinic anion (cacodylate) linked to cysteine residues 39 and
50, phases and an initial poly-alanine model were obtained using the SHELX-C/D/E49
programs in the software suite hkl2map50. An initial search in SHELX-D revealed
four cacodylate ions and SHELX-E was used to build an initial poly-alanine trace with
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20 cycles of density modiﬁcation and a solvent content of 50%. After that, phenix
autobuild51, 52 was used to build the initial model. Further model building was done
in COOT53 and reﬁnement was done with REFMAC554 in the
CCP4-suite55, phenix reﬁne56 and BUSTER (version 2.10.2. Cambridge, United
Kingdom: Global Phasing Ltd). Table 1 shows the data processing and reﬁnement
parameters. Structure alignments of the two monomers in the asymmetric unit and
external restraints were generated by ProSMART57, buried surface area was calculated
with PISA58, and the interacting residues were drawn with Ligplot+59. To analyze the
superhelical parameters of the structure we used the make_symmdef_ﬁle.pl script
from the Rosetta Symmetry framework60 in combination with the Cα model from the
asymmetric unit. All structural ﬁgures were generated in Pymol61.
NMR spectroscopy. The following NMR spectrometers were used for measuring
the NMR experiments in this study—Bruker AVIII-500 MHz, AVIII-600 MHz,
AVIII-700 MHz, and Avance-900 MHz that were equipped with cryoprobes.
TopSpin2.1/TopSpin3.0 (Bruker) was used to perform data processing while the
analysis was done in Sparky (http://www.cgl.ucsf.edu/home/sparky). For TDP-43
NTD backbone assignments, the following NMR experiments were measured
(in H2O)—two-dimensional (2D) 15N–1H HSQC, 2D 13C–1H HSQC, three-
dimensional (3D) HNCA, 3D HNCOCA, 3D CACBCONH, 3D HCcH TOCSY,
3D hCCH TOCSY, 3D 15N-, and 13C-edited Nuclear Overhauser SpectroscopY
(NOESYs).
Electron microscopy. Puriﬁed wild type and mutant TDP-43 NTD (100–500 μM)
were applied to carbon-coated grids, stained with 2% (w/v) uranyl acetate and
analyzed at various magniﬁcations on 100 kV transmission electron microscope
(Philips CM 100).
Cell culture and transient transfections and immunostaining. Mouse motor
neuron-like hybrid cell line (NSC-34, Bioconcept, Catalog number—CLU140)
were grown on cell culture dishes coated with matrigel in Dulbecco’s modiﬁed
Eagle’s/F-12 medium (DMEM) supplemented with 10% fetal bovine serum, at
37 °C in an atmosphere of 5% CO2. Mouse multipotent neural progenitor or stem-
like C17.2 cells (Sigma, Catalog number—07062902) were grown on cell culture
dishes in DMEM supplemented with 10% fetal bovine serum and 1% NEAA, at
37 °C in an atmosphere of 5% CO2. Both NSC-34 and C17.2 cell lines were
authenticated by the respective sources and were checked for Mycoplasma con-
tamination in our laboratory.
For RNA splicing rescue experiments, transfections for transient over-expression
of each vector (5 μg of DNA/2*106cells) was obtained with Lipofectamine 2000
(Life technologies) according to the manufacturer’s instruction. After 12 h
incubation with transfection reagents, the medium was replaced with normal
growth medium. Depletion of endogenous mouse TDP-43 was performed by RNA
interference as described previously38. The sequence of TDP-43 siRNA used is
5′-AGGAAUCAGCGUGCAUAUAUU-3′ and were used at 20 nM concentration.
The sequence of control siRNA used is 5′-GUGCACAUGAGUGAGAUUU-3′.
For quantiﬁcation of phosphorylated TDP-43 (pTDP-43), NSC-34 cells were
plated on 24-well (ibidi) cell culture-plates at a density of ~ 5*105 cells per well
leading to a conﬂuency of approximately 80% at time of transfection. Prior to
transfection, the cells were checked for conﬂuency and morphology and the media
was changed. Transfection was done with Lipofectamine 2000 transfection reagent
according to the manufacturer’s protocol and 0.25 µg of DNA per well was added.
Cells were maintained at 37 °C under a humidiﬁed atmosphere of 5% CO2 for 24 h
before ﬁxing them with 4% PFA for 10 min. For immunostaining, the cells were
ﬁrst permeabilized and blocked for 1 h with 10% DS and 0.2% Triton X-100 in PBS.
Primary antibodies in PBS with 10% DS, 0.2% Triton X-100 were added and
incubated for 2 h at RT. Cells were washed with PBS before incubating them with
secondary antibodies for 1 h at RT and subsequently washed with PBS. After
washing, coverslips were mounted with ProLong anti-fade medium with DAPI
(Life technologies) and the plate was kept for at least 24 h in the dark before
imaging. For the bipartite and tripartite GFP complementation assays, C17.2 cells
were transiently transfected directly on poly-D-lysine-coated 8-well microscope
slides with Lipofectamine 3000 and a total of 0.3 µg of DNA per well. Cells were
ﬁxed 24 h later with 4% PFA followed by treatment with 0.3% Triton X-100 and 5%
normal goat serum in PBS. Immunostaining was performed with anti-human
TDP-43 primary monoclonal antibody and secondary anti-mouse IgG Alexa594.
Reconstituted GFP was directly visualized by ﬂuorescence emission.
RNA extraction and quantitative reverse transcription (RT)-PCR. Total RNA
from NSC-34 cells was obtained using TRIzol (Life Technologies) according to the
manufacturer’s instructions. Complementary DNA was generated from the total RNA
(extracted from NSC-34 cells) using oligo-dT primers and Superscript III reverse
transcriptase (Life technologies) as instructed by the manufacturer. Candidate TDP-
43 splicing targets were tested by RT-PCR ampliﬁcation using 24–27 cycles with
speciﬁc primers (Supplementary Table 2) using Taq DNA polymerase (Thermo sci-
entiﬁc). RT-PCR reaction products were analyzed on 10% polyacrylamide gels
following staining with SYBR gold reagent (Life technologies). Quantiﬁcation of
distinct splice isoforms was done using ImageJ software (US National Institutes of
Health). Finally, ratios of intensity between RT-PCR products with exon inclusion
and exclusion were averaged for four biological replicates per condition.
Sequential insolubility assay. One 10 cm petri dish of cells transfected as
described above was used for each sequential extraction of proteins with buffers of
increasing stringency. Cells were harvested by scraping in solubilization buffer
(SB: 10mM Tris pH 7.4, 150mM NaCl, 0.5 mM EDTA, 1 mM DTT, complete
EDTA-free protease inhibitors (Roche). Total protein concentrations were
measured and 1mg of total protein was used for the SIA. Samples were treated with
Benzonase (250 units per sample in 2 mM MgCl2, 30 min at 4 °C (Roche)) before,
and at each solubilization phase of SIA. For each step, samples were centrifuged for
30 min at 16,000×g at 4 °C. After removing the supernatant (soluble material),
pellets (insoluble material) were suspended in SB 1% v/v Nonidet P40 Substitute
(NP-40, Sigma), SB 2% w/v dodecyl-ß-D-maltoside (Sigma), SB 2% w/v N-Laur-
oylsarcosine (Sarkosyl, Sigma) and SB 1% w/v sodium dodecyl sulfate (SDS, Sigma)
sequentially. SDS insoluble material was suspended in SB 1x SDS blue loading buffer
(Life Technologies).
Data availability. Coordinates and structure factors have been deposited in the
Protein Data Bank with accession code 5MDI. The chemical shift assignments for
TDP-43 NTD have been deposited in the BioMagResBank (BMRB) under the
accession number 27072. All other data are available from the corresponding
author upon reasonable request.
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